Presentation is loading. Please wait.

Presentation is loading. Please wait.

A) RON tyrosine kinase receptor structure; highlighted are the two somatic mutations detected in brain secondary lesions from lung cancers (R1136C and.

Published byRosalind Wheeler Modified over 5 years ago

Similar presentations

Presentation on theme: "A) RON tyrosine kinase receptor structure; highlighted are the two somatic mutations detected in brain secondary lesions from lung cancers (R1136C and."— Presentation transcript:

1 a) RON tyrosine kinase receptor structure; highlighted are the two somatic mutations detected in brain secondary lesions from lung cancers (R1136C and P1162S) and R1335G polymorphism (NCBI rs ). b) Details on somatic mutations and recurrent single nuc... a) RON tyrosine kinase receptor structure; highlighted are the two somatic mutations detected in brain secondary lesions from lung cancers (R1136C and P1162S) and R1335G polymorphism (NCBI rs ). b) Details on somatic mutations and recurrent single nucleotide polymorphism (SNP). c) Bioinformatics prediction of pathogenic role of the changes found. IPT: immunoglobulin-plexin-transcription; PM: plasma membrane; SEMA: semaphorin; TK: tyrosine kinase. Melissa Milan et al. ERJ Open Res 2018;4: ©2018 by European Respiratory Society

Download ppt "A) RON tyrosine kinase receptor structure; highlighted are the two somatic mutations detected in brain secondary lesions from lung cancers (R1136C and."

Similar presentations

Testing algorithm integrating diagnostic and predictive analysis in nonsmall cell lung cancer (NSCLC). Testing algorithm integrating diagnostic and predictive.

Testing algorithm integrating diagnostic and predictive analysis in nonsmall cell lung cancer (NSCLC). Testing algorithm integrating diagnostic and predictive.
A) IS6110 restriction fragment length polymorphism (RFLP) and b) spoligotyping patterns of a multidrug-resistant tuberculosis (MDR-TB) cluster. a) IS6110.

A) IS6110 restriction fragment length polymorphism (RFLP) and b) spoligotyping patterns of a multidrug-resistant tuberculosis (MDR-TB) cluster. a) IS6110.
Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
Representation of the 15 selected premature termination codons (PTCs) and their corresponding recoded major protein. Representation of the 15 selected.

Representation of the 15 selected premature termination codons (PTCs) and their corresponding recoded major protein. Representation of the 15 selected.
Figure 1 The multidomain structure of c-MET and its ligand, HGF

Figure 1 The multidomain structure of c-MET and its ligand, HGF
Echocardiography view

Echocardiography view
Discoidin domain receptor (DDR)2 protein was highly expressed in the lungs of patients with interstitial lung disease (ILD). Discoidin domain receptor.

Discoidin domain receptor (DDR)2 protein was highly expressed in the lungs of patients with interstitial lung disease (ILD). Discoidin domain receptor.
Overall survival from enrolment according to operating rule and scenario of organ scarcity for a) scenario R96 (i.e. 96 organs for 100 virtual patients.

Overall survival from enrolment according to operating rule and scenario of organ scarcity for a) scenario R96 (i.e. 96 organs for 100 virtual patients.
Mouth pressure (Pmo), flow rate and mean arterial blood pressure (Pa) data during a single lung volume recruitment manoeuvre in representative subjects.

Mouth pressure (Pmo), flow rate and mean arterial blood pressure (Pa) data during a single lung volume recruitment manoeuvre in representative subjects.
Compliance of the respiratory system (Crs) at baseline and 0 h, 1 h and 2 h following lung volume recruitment. a) Absolute Crs in the respiratory muscle.

Compliance of the respiratory system (Crs) at baseline and 0 h, 1 h and 2 h following lung volume recruitment. a) Absolute Crs in the respiratory muscle.
Flowchart for calculating the relative risk (RR) for cancer X and lung cancer (LC). Flowchart for calculating the relative risk (RR) for cancer X and lung.

Flowchart for calculating the relative risk (RR) for cancer X and lung cancer (LC). Flowchart for calculating the relative risk (RR) for cancer X and lung.
Kaplan–Meier curves of 12-month survival after an index chronic obstructive pulmonary disease-related hospitalisation according to level of moderate and.

Kaplan–Meier curves of 12-month survival after an index chronic obstructive pulmonary disease-related hospitalisation according to level of moderate and.
Change from baseline in trough forced expiratory volume in 1 s (FEV1) (per-protocol population). Change from baseline in trough forced expiratory volume.

Change from baseline in trough forced expiratory volume in 1 s (FEV1) (per-protocol population). Change from baseline in trough forced expiratory volume.
Distribution of forced expiratory volume in 1 s (FEV1) relative to Global Lung Function Initiative reference values (GLI2012) [10] expressed as FEV1 %

Distribution of forced expiratory volume in 1 s (FEV1) relative to Global Lung Function Initiative reference values (GLI2012) [10] expressed as FEV1 %
Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.

Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.
Prevalence of true-positive, false-negative and false-positive cases of chronic obstructive pulmonary disease identified with the fixed-limit Global Initiative.

Prevalence of true-positive, false-negative and false-positive cases of chronic obstructive pulmonary disease identified with the fixed-limit Global Initiative.
Schematic representation of main EGFR-TKIs resistance mechanisms.

Schematic representation of main EGFR-TKIs resistance mechanisms.
A) CT scan of patient number 1, before pembrolizumab; b) CT scan of patient number 1, after 11 pembrolizumab infusions; c) CT scan of patient number 1,

A) CT scan of patient number 1, before pembrolizumab; b) CT scan of patient number 1, after 11 pembrolizumab infusions; c) CT scan of patient number 1,
Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) were constructed based on.

Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) were constructed based on.

Similar presentations

Ads by Google